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The selective association of the herpesvirus trans-activator VP16 with the human Oct-1 homeo domain is a 
model for differential positive transcriptional control by homeo domains. VP16 discriminates between the 
closely related homeo domains of Oct-1 and Oct-2 by distinguishing among their seven amino-acid 
differences; these differences lie on the surface that is thought to be accessible when the homeo domain is 
bound to DNA. Only two of these seven differences are recognized by VP16, one in each of the first two 
~-helices of the tri-~-helical homeo domain. The major determinant for selective association with VP16 in 
vitro and VP16-induced positive control in vivo is a single glutamic acid residue at position 22 in the first 
~-helix of the Oct-1 homeo domain, but the acidic properties of this residue are not critical for association 
with VP16 in vitro or in vivo, because it can be replaced by glutamine with little or no deleterious effect. 
Mere replacement of the single corresponding alanine residue in the Oct-2 homeo domain with the key 
glutamic acid residue is sufficient to confer on the Oct-2 homeo domain the ability to associate with VPI6 in 
vitro and respond to VP16-induced positive control in vivo. Thus, the specificity of homeo domain positive 
control can be conferred by a single amino acid difference. 
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The 60-amino-acid homeo domain is a critical determi- 
nant of the regulatory capacity of homeo domain pro- 
teins (for review, see Hayashi and Scott 1990). Its tran- 
scriptional regulatory specificity, however, cannot be 
fully explained by its DNA-binding specificity. Selective 
interactions with regulatory cofactors are likely to be 
additional key determinants of homeo domain specific- 
ity, although the manner by which such specificity is 
achieved is not precisely known. 
An example of selective homeo domain-cofactor in- 
teraction is the differential ability of the closely related 
homeo domains of the human POU proteins Oct-1 and 
Oct-2 to associate in a multiprotein-DNA complex with 
the herpes simplex virus (HSV) trans-activator VP16 
(Stem et al. 1989; Katan et al. 1990; Kristie and Sharp 
1990; Stern and Herr 1991). Oct-1 and Oct-2 are mem- 
bers of the POU family of homeo domain proteins in 
which a POU-specific region together with the homeo 
domain form a bipartite DNA-binding domain called the 
POU domain (Herr et al. 1988; Sturm and Herr 1988). 
The POU domains of Oct-1 and Oct-2 are very similar 
and display similar, if not identical, DNA-binding prop- 
erties (Staudt et al. 1986; Aurora and Herr 1992). VP16 
(also called Vmw65 and o~-TIF) selectively associates 
with Oct-1 by distinguishing among seven Oct-1 and 
Oct-2 homeo domain differences that are thought o be 
accessible when Oct-1 or Oct-2 is bound to DNA (Stern 
et al. 1989). This selective association exemplifies one 
mechanism by which proteins that display the same 
DNA-binding specificity, such as Oct-1 and Oct-2, can 
differentially regulate transcription (for review, see Herr 
1992). 
The homeo domain is a tri-c,-helical structure belong- 
ing to the helix-turn-helix superfamily of DNA-binding 
domains. The helix-turn-helix superfamily includes the 
DNA-binding domains of prokaryotic transcriptional 
regulators uch as that of k repressor (for review, see 
Pabo and Sauer 1992). The precise structure of the Oct-1 
homeo domain is not known, but it is likely to be very 
similar to that of other homeo domains (see Wolberger et 
al. 1991). Figure 1 shows the position and identity of the 
seven differences between the Oct-1 and Oct-2 homeo 
domains uperimposed on a diagram of the engrailed ho- 
meo domain bound to DNA (Kissinger et al. 1990). Two 
of the seven Oct-1 and Oct-2 homeo domain differences 
(the two positions in helix 2 marked by asterisks in Fig. 
1) lie in positions analogous to the sites of positive con- 
trol mutations in the k repressor. In the k repressor, pos- 
itive control mutations lie within the DNA-binding do- 
main and disrupt its ability to activate xpression of its 
own gene but have little, if any, effect on DNA binding 
(Guarente et al. 1982; Hawley and McClure 1983; 
Hochschild et al. 1983). Similar types of DNA-binding 
domain mutations in eukaryotic transcriptional regula- 
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Figure 1. The positions and identities of Oct-1 amino acids 
that differ from the Oct-2 homeo domain are indicated on an 
illustration of the engrailed homeo domain bound to the major 
groove of DNA (stippled) [adapted from Kissinger tal. (1990)]. 
The three homeo domain (x-helices (1-3) are drawn as bold cyl- 
inders. The seven amino-acid differences between Oct-1and 
Oct-2 homeo domains are circled. The identities and positions 
of Oct-1 residues are indicated followed by theidentities of the 
amino acids in the Oct-2 homeo domain at the corresponding 
positions. The amino acids are numbered according to the con- 
vention used by Kissinger et al.(1990). The asterisks (*} identify 
the homologous positions of positive control mutations in the 
repressor (Hochschild et al. 1983). (N) amino terminus; (C)car- 
boxyl terminus. 
tors have also been referred to as positive control muta- 
tions (Schena et al. 1989; Stem et al. 1989). As in the 
repressor, one or more residues involved in association 
with VP16, and, hence, probably positive control, lie 
within helix 2, although Oct-1 residues outside of helix 
2 are also involved in VP16 association (Stern et al. 1989). 
Here, we identify the individual contribution of each 
of the seven amino-acid ifferences between the Oct-1 
and Oct-2 homeo domains for selective association with 
VP16 in vitro. The results show that a single glutamic 
acid for alanine difference in helix 1 is the key determi- 
nant by which VP16 discriminates between the Oct-1 
and Oct-2 homeo domains. Transfer of this single amino 
acid to the Oct-2 homeo domain is sufficient o support 
VP16-induced complex formation in vitro and VP16-in- 
duced positive control in vivo. 
Resu l ts  
A single glutamic acid residue is the key 
determinant for selective association of the Oct-1 
homeo domain with VP16 
To identify which of the seven differences between the 
Oct-1 and Oct-2 homeo domains are responsible for the 
differential ability of Oct-1 and Oct-2 to associate with 
VP16, we individually exchanged each of the seven 
amino-acids in the Oct-1 homeo domain for its Oct-2 
counterpart, as indicated in Figure 1, and assayed its ef- 
fect on association with VP16. We refer to the amino 
acid exchanges by the singleqetter code and position of 
the wild-type residue followed by the single-letter code 
of the replacing amino acid. Thus, in the E22A exchange 
the glutamic acid residue at position 22 of the Oct-1 
homeo domain has been replaced by the Oct-2-derived 
alanine residue at this position. VP16-induced complex 
formation was assayed by electrophoretic mobility re- 
tardation with VP16 and an auxiliary host cell factor 
called HCF, C1, VCAF, or CCF (Gerster and Roeder 
1988; Kristie et al. 1989; Katan et al. 1990; Xiao and 
Capone 1990; Stern and Herr 1991) on a probe from 
the HSV ICP0 promoter (Gerster and Roeder 1988; Stem 
and Herr 1991) containing the cis-acting target of VP16 
activation, the TAATGARAT (R = purine) motif. This 
TAATGARAT site contains an overlapping octamer mo- 
tif, which serves as a binding site for Oct-1 and Oct-2 in 
the absence of VP16 and which we refer to as an 
(OCTA + )TAATGARAT site. The auxiliary host cell fac- 
tor (HCF) stimulates VP16-induced complex formation 
and is a component of the VP16-induced complex, but 
VP16 is responsible for discriminating between the 
Oct-1 and Oct-2 homeo domains (Stern and Herr 1991; 
Pomerantz et al. this issue). 
Figure 2 shows the result of an assay for DNA binding 
and VP16 association with the variant Oct-1 POU do- 
mains. As expected, the Escherichia coli-derived gluta- 
thione S-transferase (GST)-POU domain fusion proteins 
containing either the wild-type Oct-1 POU domain or an 
Oct-1 POU domain carrying the Oct-2 homeo domain 
sequence (Oct-1/Ho2) display similar affinity for the 
(OCTA+)TAATGARAT probe (of. lanes 2 and 10). Fur- 
thermore, none of the 7 single amino acid replacements 
has an obvious effect on DNA binding either in the assay 
shown in Figure 2 (lanes 3-9) or at lower concentrations 
of the POU-domain protein (data not shown). In the as- 
say for VP16-induced complex formation, however, the 
wild-type Oct-1 POU domain (lane 11), but not he Oct- 
1/Ho2 POU domain (lane 19), formed the VP16-induced 
complex. Only 2 of the 7 individual amino acid replace- 
ments (lanes 12-18) affected VP 16-induced complex for- 
mation. The replacement of glutamic acid with alanine 
in helix 1 (E22A) had a dramatic effect, resulting in little 
evident complex formation with VP16, whereas the re- 
placement of methionine with leucine in helix 2 (M33L) 
had a twofold effect. Similar effects have also been ob- 
served by Pomerantz et al. (this issue). 
To determine whether either one or both of the Oct-1 
E22 and M33 residues are sufficient for VP16 to discrim- 
inate between the Oct-1 and Oct-2 homeo domains, we 
asked whether VP16 can recognize an Oct-2 homeo do- 
main carrying one or both of these residues. We replaced 
the Oct-2 alanine residue at position 22 with a glutamic 
acid residue alone [Oct-1/Ho2(A22E)] or in combination 
with a methionine residue at position 33 [Oct-l/ 
Ho2(A22E + L33M)]. Figure 3 shows the effect of these 
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Figure 2. A glutamic acid residue at position 22 of the Oct-1 
homeo domain is the key determinant for VP16 discrimination 
of the Oct-1 and Oct-2 homeo domains. An electrophoretic mo- 
bility retardation assay for VIC formation was performed for 
Oct-1 POU domain proteins containing individual residues ex- 
changed for their Oct-2 counterpart. The identity of the amino 
acid exchange for each POU domain is indicated at the top of 
each lane as described in the text (see also Fig. 1). Each variant 
Oct-1 POU domain protein was used in a reaction either in the 
absence {lanes 2-10) or presence {lanes 11-19) of GST-VP16AC 
fusion protein and HCF. {Lane 1) (OCTA + )TAATGARAT probe 
alone. The positions of the free (OCTA+)TAATGARAT probe 
(Free Probe), denatured single-stranded probe (S.S.}, Oct-1 POU 
domain/DNA complex (POU), and VP16-induced complexes 
(VIC) are shown at left. 
two replacements on the ability of the Oct-2 homeo do- 
main to associate with VP16. As expected, the 
replacements had little evident effect on binding to the 
(OCTA+)TAATGARAT probe alone (lanes 1-5). Intro- 
duction of the single glutamic acid residue (A22E), how- 
ever, resulted in -50% of the wild-type VP16 association 
activity, an effect also described by Pomerantz et al. (this 
issue), whereas the combination of the two exchanges 
(A22E + L33M) resulted in full activity (lanes 6-9). 
Thus, in this assay, only these two residues allow VP16 
to discriminate between the human Oct-1 and Oct-2 ho- 
meo domains. However, whereas the methionine residue 
at position 33 does not support effective association with 
VP16 in the absence of the glutamic acid residue at po- 
sition 22 (Fig. 2, lane 14), the key glutamic acid residue is 
sufficient o support effective association of the Oct-2 
homeo domain with VP16. 
The key glutamic acid residue can be replaced 
by glutamine but not by aspartic acid with little 
effect on association with VP16 in vitro 
To identify important features of the key glutamic acid 
residue at position 22 for association with VP16, we re- 
placed this residue with a selected set of residues found 
naturally in other POU homeo domains. For comparison, 
Figure 4B shows the structure of 2 of the 3 amino acid 
replacements ogether with the structures of the Oct-1 
glutamic acid and Oct-2 alanine residues. In one case, we 
replaced the glutamic acid residue with a glutamine res- 
idue (E22Q), as is found in the nematode tmc86 POU 
homeo domain (Finney et al. 1988); glutamine is similar 
in size to glutamic acid but is uncharged owing to the 
replacement of the hydroxyl group for an amino group. In 
the other case, we replaced the glutamic acid residue 
with an aspartic acid residue (E22D), as is found in the 
murine Oct-11 POU homeo domain (Goldsborough et al. 
1990); aspartic acid maintains the negative charge of glu- 
tamic acid but shortens the side chain. We also created a
more drastic alteration by replacing the glutamic acid 
residue with a positively charged lysine residue (E22K), 
as is found in the murine Oct-3/4 POU homeo domain 
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Figure 3. A single glutamic acid substitution for alanine 22 in 
helix 1 of the Oct-2 homeo domain supports VIC formation by 
the Oct-2 homeo domain. An electrophoretic mobility retarda- 
tion assay for VIC formation was performed with wild-type 
Oct-1 POU domain carrying the Oct-2 homeo domain {Oct-l/ 
Ho2; lanes 2, 6), Oct-1/Ho2 carrying the glutamic acid for ala- 
nine exchange at position 22 [Oct-1/Ho2(A22E); lanes 3, 7], the 
double substitutions of alanine and leucine residues with glu- 
tamic acid and methionine [Oct-1/Ho2(A22E + L33M); lanes 4, 
8], and wild-type Oct-1 POU domain protein {lanes 5, 9) either 
in the absence (lanes 2-5) or presence (lanes 6-9) of GST- 
VP16AC fusion protein and HCF. (Lane 1) Free (OCTA+) -
TAATGARAT probe. The positions of the different electropho- 
retie species are as described in the legend to Fig. 2. 
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Figure 4. The glutamic acid residue at position 22 
of the Oct-1 homeo domain can be replaced by glu- 
tamine, but not by aspartic acid or lysine, with little 
effect on association with VP16. (A) An electropho- 
retic mobility retardation assay for VIG formation 
was performed with wild-type Oct-1 POU domain 
(lanes 2, 7, 8, 13), or Oct-1 POU domain carrying the 
substitution of the glutamic acid residue at position 
22 with alanine (E22A; lanes 3, 9), lysine (E22K; 
lanes 4, 10), aspartic acid (E22D; lanes 5, 11 ), or glu- 
tamine (E22Q; lanes 6, 12) in a reaction either in the 
absence (lanes 2-7) or presence (lanes 8-13) of GST- 
VP16AC fusion protein and HCF. {Lane 1) Free 
(OCTA + )TAATGARAT probe; (B) a schematic rep- 
resentation of the structures of the glutamic acid (E), 
glutamine (Q), aspartic acid (D), and alanine (A) side 
chains. 
(Okamoto et al. 1990; Rosner et al. 1990; Sch61er et al. 
1990). 
Figure 4A shows the DNA-binding and VP16 associa- 
tion activity of these three glutamic acid replacements. 
None of these replacements adversely affected binding to 
the (OCTA +)TAATGARAT probe (lanes 1-7), although 
the presence of an acidic (g or D; lanes 8, 11), neutral (A 
or Q; lanes 9, 12), or basic (K; lane 10) residue at this 
position affected the mobility of the POU domain-DNA 
complex slightly, probably owing to slight changes in the 
overall charge of the POU domain-DNA complex. In the 
assay for association with VP16, however, the Oct-1 
POU domains carrying either the lysine or aspartic acid 
residues were inactive (lanes 10, 11). Thus, an acidic res- 
idue at this position is not sufficient for association with 
VP16 in vitro. Acidity is also not essential for association 
with VP16 because the Oct-1 POU domain carrying the 
glutamine residue at this position displays near wild- 
type activity (80%) (lane 12). Thus, it is likely that hy- 
drogen bonding or hydrophobic interactions with the 
glutamic acid residue are important for the interaction 
with VP 16. 
A single amino acid difference is sufficient 
for selective positive control by the Oct-1 
and Oct-2 homeo domains in the presence of VP16 
To measure the effects of selected amino acid swaps be- 
tween the Oct-1 and Oct-2 homeo domains on VP16- 
dependent positive control, we took advantage of a re- 
cently developed in vivo transient expression assay in 
mouse cells {M. Cleary, S. Stern, M. Tanaka, and W. 
Herr, in prep.). VP16 does not activate transcription as 
effectively in mouse cells as in human cells, probably 
because the murine Oct-1 homeo domain differs from 
the human Oct-1 homeo domain at four positions 
(Goldsborough et al. 1990; Stepchenko 1992). As a result, 
when the human Oct-1 POU domain, but not an Oct-1 
POU domain carrying the Oct-2 homeo domain, is ex- 
pressed in murine NIH-3T3 cells, VP16 activation is 
stimulated - 10-fold, thus establishing that the Oct- 1 ho- 
meo domain is involved in positive control in vivo (M. 
Cleary, S. Stern, M. Tanaka, and W. Herr, in prep.). 
This result is illustrated in Figure 5 (lanes 1-4, 9). Two 
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r - - - I  I 1 i t I 
~ +  
POU I I ~ ~ w ~ ~ r  T -v T I W W W 
IX - -  
I 2 3 4 5 6 7 8 9 iO I1 12 13 14 15 
Figure 5. In vivo VP16-induced positive control by Oct-1 and 
Oct-2 homeo domain chimeras and variants. The [3-globin re- 
porter plasmid, a-globin i ternal reference plasmid, and wild- 
type or variant Oct-1 POU domain effector plasmid {as indicated 
at the top of each lane I were transfected into NIH-3T3 cells 
either in the absence (lanes 1, 3) or presence {lanes 2, 4-15/of 
the VP16 expression plasmid, and RNA expression was ana- 
lyzed by RNase protection as described in Materials and meth- 
ods. Bands corresponding to correctly initiated c~-globin tran- 
scripts (~), f3-globin transcripts ([3), and incorrect readthrough 
(RT) transcripts are indicated. Samples w re adjusted (no more 
than --- two- to threefold) to equalize the e~-globin signal. 
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reporter plasmids, one containing the human oL-globin 
transcription unit as an internal reference for transfec- 
tion efficiency, and the other containing the human 
[3-globin gene with multimerized VP16 responsive 
TAATGARAT motifs upstream of the transcriptional 
start site (see Materials and methods), were cotrans- 
fected into NIH-3T3 cells either in the presence or ab- 
sence of effector constructs expressing Oct-1 POU do- 
main derivatives and/or VP16. VP16 alone activated 
transcription of this [3-globin reporter ineffectively (lanes 
1, 2), but in the presence of the human Oct-1 POU do- 
main (lanes 3, 4) VP16 activation was elevated sevenfold 
(cf. lanes 2 and 4). No such stimulation was observed in 
the presence of the Oct-1 POU domain carrying the 
Oct-2 homeo domain (lane 9). This differential VP16- 
induced activation provides a sensitive assay to measure 
the effects of amino acid swaps between the Oct-1 and 
Oct-2 homeo domains on positive control in vivo. 
To ensure that observed effects were not the result of 
poor expression or stability of one of the Oct-1 or Oct-2 
homeo domain derivatives, we monitored the levels of 
transient POU domain expression by preparing cell ex- 
tracts from a portion of the transfected cells and perform- 
ing an electrophoretic mobility retardation assay. This 
assay also measured the ability of the transiently ex- 
pressed POU domain proteins to associate with VP16. 
The results showed that the various POU domain vari- 
ants were expressed at similar levels and that even 
though they were produced in mammalian cells, their 
relative ability to associate with VP16 paralleled the 
VP16-association activities of the E. coli-produced pro- 
teins described above (data not shown). 
Figure 5 shows that the positive control activities par- 
allel the ability of the various Oct-1 homeo domain de- 
rivatives to associate with VP16, except that in the in 
vivo activation assay the effects of deleterious mutations 
are less disruptive than those in the in vitro assay. This 
quantitative difference may reflect different stringencies 
for Oct-1 association with VP16 in the two different as- 
says. Of the four single amino acid replacements of Oct-1 
for Oct-2 tested (lanes 5-8), only the replacement of 
E22A glutamic acid for alanine had a significant effect on 
VP16 activation (lane 5); the three individual exchanges 
in helix 2 (T32L, M33L, and D36E) had little, if any, 
effect on VP16 activation (lanes 6-8). Furthermore, the 
combination of all three Oct-1 helix 2 residues in the 
context of the Oct-2 homeo domain only displays mod- 
est activity [Ho2(He2-1); lane 11], whereas transfer of the 
single critical Oct-1 glutamic acid residue (with or with- 
out the helix 2 methionine at position 33) to the Oct-2 
homeo domain resulted in a wild-type VP16 response (cf. 
lanes 10 and 12 with lanes 4 and 9). Consistent with the 
in vitro assays (see Fig. 4), lysine, but not glutamine, at 
position 22 of the Oct-1 homeo domain disrupts VP16- 
induced positive control (lanes 13, 15J. The aspartic acid 
residue at position 22 also disrupts VP16-induced posi- 
tive control (lane 14), albeit to a lesser extent than the 
lysine (lane 13) or alanine (lane 5) substitutions, uggest- 
ing that it has a less deleterious effect on association 
with VP16 than these other mutations. Together, these 
results show that the activity of amino acid swaps or 
replacements for VIC assembly in vitro and VP16-in- 
duced activation in vivo correlate and show most signif- 
icantly that a single amino acid exchange, A22E, is suf- 
ficient to transfer VP16-induced positive control from 
the Oct-1 to the Oct-2 homeo domain. 
Discussion 
There are now numerous instances in which DNA-bind- 
ing domain mutations affect transcriptional ctivation 
without eliciting a corresponding defect in DNA bind- 
ing. Examples include mutations in the DNA-binding 
domains of the glucocorticoid receptor (Hollenberg and 
Evans 1988; Schena et al. 1989), the yeast activator 
HAP1 (Kim and Guarente 1989), MyoD (Weintraub et al. 
1991; Davis and Weintraub 1992), and myogenin 
{Schwarz et al. 1992). Such positive control mutations 
are analogous to mutations within the k repressor DNA- 
binding domain that affect interactions with RNA poly- 
merase to stimulate transcription but do not affect DNA 
binding (Guarente et al. 1982; Hawley and McClure 
1983; Hochschild et al. 1983). The regulatory target af- 
fected by the positive control mutations in these eukary- 
otic activators has not been identified, however. Thus, 
VP16-induced positive control by Oct-1 represents a
unique case where the effects of DNA-binding domain 
mutations on positive control can be correlated with the 
effects on association with the regulatory target (this re- 
port; M. Cleary, S. Stem, M. Tanaka, and W. Herr, in 
prep.). 
The analysis of positive control mutations in Oct-1 
has been aided greatly by the existence of its close rela- 
tive Oct-2, which displays the same DNA-binding spec- 
ificity but fails to respond to VP16 in vivo (M. Cleary, S. 
Stem, M. Tanaka, and W. Herr, in prep.) or to associate 
with VP16 in vitro (Gerster and Roeder 1988). The ability 
to compare and contrast Oct-1 and Oct-2 association 
with VP16 serves to elucidate how homeo domains can 
effect differential positive control while recognizing the 
same DNA sequence. The finding here that a single 
amino acid difference between two homeo domains, in 
this instance a glutamic acid for alanine difference, can 
direct the differential transcriptional response of two ho- 
meo domain proteins to a regulatory cofactor shows how 
simple it is to confer transcriptional ctivation specific- 
ity through selective homeo domain-cofactor interac- 
tion. 
Although the glutamic acid residue at position 22 of 
the Oct-1 homeo domain is the key determinant by 
which VP16 discriminates between Oct-1 and Oct-2, it is 
not the sole determinant for VP16 association with Oct- 
1. In the accompanying study, Pomerantz et al. (this is- 
sue) show that at least three other positions within the 
Oct-1 homeo domain (K18, $19, and E30), positions that 
are identical between Oct-1 and Oct-2, are as important 
for association with VP16 as the glutamic acid residue at 
position 22. The ability of single amino acid residues to 
influence protein association greatly suggests that they 
form part of a tight interface between the Oct-1 homeo 
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domain and VP16. The interface with the discriminating 
glutamic acid residue at position 22 is l ikely to involve 
hydrophobic and/or hydrogen bonding interactions 
rather than ionic ones because it can be replaced by glu- 
tamine without any significant effect on association 
with VP 16. This property may be unique to this position, 
however, because replacement of the glutamic acid res- 
idue at position 30 in helix 2 with glutamine has a dra- 
matic effect on Oct-1 association with VP16 {Pomerantz 
et al. this issuel. 
The individual contributions of all seven amino-acid 
differences between the Oct-1 and Oct-2 homeo domains 
for association with VP16 identified here are consistent 
with our previous analysis {Stem et al. 1989), in which 
we reciprocally exchanged the three differing residues in 
helix 2 between Oct-1 and Oct-2. The results of that 
study showed that VP16 association with Oct-1 is de- 
pendent on one or more of the three Oct-l-specific resi- 
dues in helix 2 but that these residues are not sufficient 
to induce Oct-2 association with VP 16. Those results are 
explained by the disruptive ffect of the M33L exchange 
in helix 2 and the critical importance of the glutamic 
acid residue in helix 1. 
In the previous study, however, the deleterious effect 
of exchanging helix 2 in Oct-1 for its Oct-2 counterpart 
was greater (90% loss of VP16-induced complex) than 
when the same helix 2 swap was retested in our current 
study {50% loss; data not shown, but see Fig. 2; see also 
Pomerantz et al. this issue}. The current comparison of 
the dramatic effect of the E22A exchange in helix 1 and 
the much smaller effect of the M33L exchange in helix 2 
{Fig. 2) places less emphasis on helix 2 for selective as- 
sociation of Oct-1 with VP16 than was attributed previ- 
ously to helix 2 {Stern et al. 1989). The quantitative dif- 
ference between our previous and current studies is prob- 
ably a result of the two different assays used to measure 
VP16-induced complex assembly. For example, in our 
previous tudy the relative levels of VP16-induced com- 
plex to Oct-1-binding activity were low owing to limit- 
ing levels of HCF activity in the reticulocyte lysates used 
to produce Oct-1 by in vitro translation, whereas in the 
current study we supplemented the binding reactions 
with partially purified HCF. 
The current results suggest hat the surface of the ho- 
meo domain/hel ix - turn-hel ix  motif used for positive 
control by the Oct-1 homeo domain and h repressor 
DNA-binding domain differs. In h repressor, mutations 
in helix 2 but not helix 1 affect positive control {Hochs- 
child et al. 1983; Bushman and Ptashne 1988; Bushman 
et al. 1989}, whereas in Oct-1 primarily replacements in 
helix 1 have a dramatic effect on association with VP16 
and positive control (see Pigs. 2, 5}; only one replacement 
in helix 2 has a dramatic effect onassociation with VP16 
{Pomerantz et al., this issue). These results suggest hat 
distinct surfaces of the homeo domain/he l ix - tum-hel ix  
motif can be involved in protein-protein teraction and 
positive control. 
In Drosophila,  homeo domain proteins form a large 
family of developmental regulatory proteins. In these 
proteins the homeo domain itself, even when very 
closely related, can direct different developmental pro- 
grams {for review, see Hayashi and Scott 1990; see also 
Lin and McGinnis 1992}. Homeo domain proteins seem 
especially suited to orchestrate such developmental reg- 
ulatory pathways, because, as il lustrated by the differen- 
tial interaction of VP 16 with the Oct-1 and Oct-2 homeo 
domains, very subtle changes--as ubtle as a single 
amino acid change--can have dramatic effects on pro- 
tein-protein interactions and transcriptional control. 
Materials and methods 
Expression constructs 
Wild-type and variant GST-Oct-1 POU domain E. coli expres- 
sion constructs, containing human Oct-1 residues 280--439 
(Sturm et al. 1988), were from a derivative of the vector 
pET1 lc.G.POU-1 (Aurora and Herr 1992) in which an fl repli- 
cation origin (Heitman et al. 1989) was inserted in the unique 
EcoRI site of pETllc (Studier et al. 1990) to produce antisense 
single-stranded DNA with respect o the Oct-1 POU domain- 
coding sequences. This pETllc derivative is referred to as 
pETllc off + (-). Mutations were created by oligonucleotide- 
directed mutagenesis (Zoller and Smith 1983; Kunkel et al. 
1987). For each mutation, a companion restriction site was ei- 
ther created or destroyed to serve as a marker for screening the 
mutations. The sequences created in the oligonucleotide-di- 
rected mutants are I12V, AACgTaCGT (RsaI +); V14F, CGTtT- 
tGCC (HaelII-); E22A, cTcGcGAAT (NruI + }; T32L, AGATCt- 
taA {BgllI + ); M33L, ACatTaATT (AseI + ); D36E, GCTGAaCAG 
(BclI-); N39H, CTCcATATG (NdeI+); E22K, CcTtaAGA 
(AflII + ); E22D, CcTcGAtA (TaqI + ); E22Q, CcTgcAGA {PstI + ), 
where the uppercase l tters represent the wild-type sequences 
and the lowercase l tters represent mutations; the three letters 
in bold encode the missense mutation; and the created {+) or 
destroyed (-} restriction sites are underlined and identified in 
parentheses. Each mutation was verified by dideoxy DNA se- 
quencing. The Oct-1/Ho2 variant containing the Oct-2 homeo 
domain represents he wild-type Oct-1 POU domain with all 
seven of the Oct-2 missense mutations described above. Like 
the Oct-1/Ho2 variant, the Oct-1/Ho2(A22E) and Oct-l/ 
Ho2(A22E + L33M) variants were made from wild-type Oct-1 
by sequential mutagenesis incorporating the 6 or 5 Oct-2 resi- 
dues into the Oct-1 homeo domain, respectively. The GST- 
VP16 derivative GST-VP16AC lacking the carboxy-terminal 
acidic activation domain (residues 413-490) was from the plas- 
mid pET1 lc.G.VP16AC, which will be described in detail else- 
where (J.-S. Lai and W. Herr, unpubl.). 
The wild-type and variant Oct- 1 POU domain expression con- 
structs for transient expression i mammalian cells (pCG---Oct- 
1-POU series) were constructed by transferring the Oct-1 POU 
domain-encoding sequences from the pETllc.G.POU-1 con- 
structs as an XbaI-BamHI fragment into the unique XbaI and 
BamHI sites of the cytomegalovirus {CMV) promoter-contain- 
ing expression vector pCG (Tanaka nd Herr 1990). The pCG- 
derived VP16 expression construct (pCG--VP16) likewise con- 
tains the VP16-coding sequences inserted between the pCG 
XbaI and BamHI sites (A. Wilson and W. Herr, unpubl.). 
POU domain and VP16 expression and purification 
The wild-type and variant GST-Oct-1 POU domain and GST- 
VP16AG fusion proteins were expressed in E. coli BL21 (DE3) 
cells by using the T7 expression system (Studier et al. 1990). For 
optimal expression of soluble fusion proteins, typically 5ml of 
ceils at  OD6o o = 0.8--1.0 were induced at 23°C overnight {-12 
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hr) with isopropyl B-D-thiogalactopyranoside. The cells were 
then harvested by centrifugation and resuspended in a one-fifth 
volume of the culture medium with a buffer containing 25 mM 
HEPES--KOH (pH 7.9), 100 mM KC1, 20% glycerol, 0.2 mM 
PMSF, 2 mM EDTA, and 2 mM DTT. Following lysozyme treat- 
ment at 4°C, NP-40 (Sigma) was added to a final concentration 
of 0.1%. The lysate was sonicated 10 times with 40-sec pulses 
(40% duty cycle), and the insoluble portion was subsequently 
pelleted by centrifugation. To purify the GST fusion proteins, 
they were bound to glutathione-agarose (Sigma; 250 ~1 of a 50% 
slurry per 1 ml of extract) at 4°C for 1 hr, washed, and eluted 
with 2 aliquots of 120 ~1 of 5 mM reduced glutathione (Sigma) in 
50 mM Tris-HC1 (pH8.0). Protein integrity, concentration, and 
purity were determined by Coomassie blue staining after SDS- 
PAGE. Typically, -150 ~g of full-length fusion protein per 5 ml 
of induced culture was obtained for the wild-type and variant 
GST-Oct-1 POU fusion proteins, whereas -10-fold less full- 
length protein was obtained for the GST-VP16AC fusion pro- 
teins. The full-length fusion protein was the major species (60- 
90%) present in each preparation; minor components were 
probably largely inactive truncation products of the full-length 
proteins. 
Electrophoretic mobility retardation assay for WC formation 
The (OCTA+)TAATGARAT probe from the HSV ICP0 pro- 
moter (Stern and Herr 1991) was prepared by polymerase chain 
reaction (PCR) as described (Aurora and Herr 1992). Fraction- 
ated human HeLa cell-derived HCF devoid of Oct-1 was a kind 
gift of A. Wilson (Cold Spring Harbor Laboratory). Equivalent 
levels of purified GST-Oct- 1 POU domain protein (-  1 ng) alone 
or with added GST-VP16AC protein (-20 ng) and HCF fraction 
{-5 ng) were mixed in a 10 ~1 reaction [10 mM Tris-HCl (pH 7.9), 
60 mM KC1, 1 mM DTT, 1 mM EDTA, 0.1% NP-40, 2% glycerol, 
2% Ficoll-400, 10 ng of sonicated salmon sperm DNA, 0.75 ~g 
of poly[d(I-C)], 3% fetal bovine serum, 20,000 cpm of 
(OCTA +)TAATGARAT probe] for 30 min at 30°C. After incu- 
bation, reactions were loaded directly onto a 4% polyacryl- 
amide (39:1 acrylamide/bisacrylamide) gel in TGE (20 mM 
Tris-HC1, 200 mM glycine, 1 mM EDTA at pH 8.3) and electro- 
phoresed at 12 V/cm for -2  hr. After electrophoresis, the gel 
was fixed, dried, and autoradiographed. Levels of VIC were 
quantitated on a Fuji BAS2000 PhosphorImager. 
Transient expression assay 
The in vivo human Oct-l-dependent VP16 activation assay in 
mouse cells will be described in detail elsewhere (M. Cleary, S. 
Stem, M. Tanaka, and W. Herr, in prep.). Briefly, 3 x 105 NIH- 
3T3 cells were seeded onto 100-mm dishes 24 hr before trans- 
fection. The [3-globin reporter plasmid (4 ~g), internal reference 
plasmid p~ 4X(A+C) (1 ~g) (Tanaka and Herr 1990), pCG oct- 
1-POU expression plasmid (0.5 ~g}, pCG-VP16 plasmid (0.5 ~g), 
and pUC119 carrier DNA (up to 20 ~g of total DNA) were trans- 
fected by calcium phosphate coprecipitation. At 48 hr post- 
transfection, the cells were harvested, resuspended in 200 ~1 of 
10 mM Tris-HC1 (pH 8.0), 150 mM NaC1, and divided into two 
portions. To prepare cytoplasmic RNA, 180 ~1 was used as de- 
scribed (Tanaka et al. 1988); and to prepare a "whole-cell nu- 
clear" extract for DNA-binding assays 20 ~1 was used as de- 
scribed (Tanaka et al. 1992). The B-globin reporter plasmid 
pU2/~A 36 contains divergent U2 small nuclear RNA (snRNA) 
and [3-globin transcription units with a multimerized 
(OCTA-)TAATGARAT site from the HSV ICP4 promoter (M. 
Cleary, S. Sterm, M. Tanaka, and W. Herr, in prep.). 
RNA expression was measured by RNase protection f radi- 
olabeled antisense RNA probes and electrophoresis of the re- 
sulting protected fragments through 6% denaturing polyacryl- 
amide gels. The c~98 probe and [3143 probe (W. Thomann and W. 
Herr, unpubl.) are protected by correctly initiated transcripts 
over 98 and 143 nucleotides, respectively. The radioactivity in 
the protected fragments was quantitated by measurement of the 
dried gels with a PhosphorImager (Fuji BAS2000), and the re- 
sults were normalized to the level of the e~-globin internal ref- 
erence xpression. Similar results were obtained in three exper- 
iments. POU domain expression and VIC formation was as- 
sayed by electrophoretic mobility retardation, as described 
above, except hat the transfected cell extract (2 ~1 out of 40 ~1) 
containing transiently expressed POU domain and/or VP 16 pro- 
teins was used in place of the GST-POU domain and GST- 
VP16AC proteins. These mouse cell extracts are limiting for 
HCF activity; therefore, they were assayed for POU domain 
expression without added human HCF and for VIC formation 
with added human HCF. 
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